Literature DB >> 18992199

[Expression of KLK6 protein and mRNA in primary breast cancer and its clinical significance].

Shou-man Wang1, Jie Mao, Bo Li, Wei Wu, Li-li Tang.   

Abstract

AIM: To investigate the expression of KLK6 protein and mRNA in primary breast carcinoma, and to evaluate its clinical significance in clinicopathological status of patients with primary breast carcinoma.
METHODS: 88 patients with primary breast carcinoma chosen randomly were examined for KLK6 protein and mRNA expression by SABC immunohistochemistry and RT-PCR, respectively. The association of KLK6 with the clinicopathologic features of the primary breast cancer was also analysis.
RESULTS: The positive expression rates of KLK6 protein in breast carcinoma tissues were 78.40% (69/88). Clinicopathological parameters of breast carcinoma were associated with KLK6 protein expression. KLK6 protein was expressed less frequently in breast carcinoma tissues with lymph nodes metastasis (P<0.01) and ER(+) (P<0.05). Additionally, the mean expression level of KLK6 mRNA in cancerous tissues was significantly higher than that in normal tissues (P<0.01). However, KLK6 mRNA expression was negatively correlated with metastasis (P<0.01) and ER status (P<0.01). The expression of KLK6 protein and mRNA in primary breast carcinoma tissues was not associated with that of CerbB-2.
CONCLUSION: KLK6 expression in cancerous tissues may play an important role in the invasion and metastasis of primary breast carcinoma. The detection of it along with clinical staging may help to predict the prognosis of patients with primary breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18992199

Source DB:  PubMed          Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi        ISSN: 1007-8738


  3 in total

1.  KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.

Authors:  Konstantinos G Sidiropoulos; Qiang Ding; Georgios Pampalakis; Nicole M A White; Peter Boulos; Georgia Sotiropoulou; George M Yousef
Journal:  Mol Oncol       Date:  2016-04-08       Impact factor: 6.603

2.  Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.

Authors:  Nancy Ahmed; Julia Dorn; Rudolf Napieralski; Enken Drecoll; Matthias Kotzsch; Peter Goettig; Eman Zein; Stefanie Avril; Marion Kiechle; Eleftherios P Diamandis; Manfred Schmitt; Viktor Magdolen
Journal:  Biol Chem       Date:  2016-12-01       Impact factor: 3.915

3.  Biochemical pathways mediated by KLK6 protease in breast cancer.

Authors:  Georgios Pampalakis; Eleni Zingkou; Konstantinos Gus Sidiropoulos; Eleftherios P Diamandis; Vassilis Zoumpourlis; George M Yousef; Georgia Sotiropoulou
Journal:  Mol Oncol       Date:  2019-09-30       Impact factor: 6.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.